We are proud to present our research at ESMO Congress in Paris, September 9th to 13th.2022.
A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)
200TiP poster Presentation Topic: Breast cancer, early stage; Date: Sat, 10.09.2022
Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies
68MO mini oral Mini Oral session: Basic science & translational research
Location: 7.1.D - Dijon Auditorium, Paris Expo Porte de Versailles, Paris, France
Date: Sun, 11.09.2022 Time: 14:45 - 16:15
Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts
151P poster Presentation Topic: Breast cancer, early stage; Date: Sat, 10.09.2022
Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
168P poster Presentation Topic: Breast cancer, early stage; Date: Sat, 10.09.2022
Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC Registry
269P poster Presentation Topic: Breast cancer, metastatic; Date: Sat, 10.09.2022
Visit the congress website for more information.